Treating a patient with widespread metastatic non-small cell lung cancer (mNSCLC) presents a very different challenge than treating one without distant disease. What is the right way to go about this? In this episode of The Fellow on Call: The Heme/Onc Podcast, the team highlights some salient points regarding how to tackle metastatic NSCLC, specifically without driver mutations. Among the highlights, the group focuses on the importance of complete staging, histology, the consideration of immunotherapy for all mNSCLC patients, and more. Overall, the group notes that for treating mNSCLC, plenty of options exist, but the ideal approach is usually a combination of chemotherapy and immunotherapy.